is the most common malignancy originating from the thyroid. Although it generally shows an indolent character and excellent prognosis, patients with aggressive characteristics are likely to show recurrence and die of carcinoma. Therefore, the accurate evaluation of clinicopathological features is important to discriminate such high-risk cases. Abstract. In this study, we investigated the difference in lymph node-recurrence free survival (LN-RFS), distant recurrence-free survival (DRFS), and cause-specific survival (CSS) between patients with papillary thyroid carcinoma (PTC) in the entire group (Group I) and those with lymph node-and distant-recurrence-free survival (DFS) for 5 years after initial surgery (Group II). The LN-RFS of patients with all risk classifications in Group II was significantly better than that of those in Group I. The LN-RFS of intermediate-risk patients in Group II did not differ from that of low-risk patients in Group I, but LN-RFS of high-risk patients in Group II was significantly poorer than intermediate-and low-risk patients in Group I. DRFS and CSS of Group II patients did not significantly differ from those of Group I patients in the same risk classification. DRFS and CSS of high-risk patients in Group II were significantly poorer than those of intermediate-and low-risk patients in Group I, and those of intermediate-risk patients in Group II were also significantly poorer than those of low-risk patients in Group I. Taken together, the lymph node recurrence rate, but not distant recurrence and carcinoma death rates, of patients in all classifications significantly improved after DFS for 5 years. However, careful follow-up for lymph node recurrence of high-risk patients and for distant recurrence of intermediate-and high-risk patients is necessary thereafter.
Improvement of lymph node recurrence rate, but not distant recurrence and carcinoma death rates, in patients with papillary thyroid carcinoma after disease-free survival for 5 years Yasuhiro Ito 1) , Takumi Kudo 2) , Minoru Kihara 1) , Yuuki Takamura 1) , Kaoru Kobayashi 1) , Akihiro Miya 1) and Akira Miyauchi 1) tumor size, lymph node metastasis detected on preoperative imaging studies, size of node metastasis, extrathyroid extension of primary lesions, and extranodal tumor extension [5] . We showed that the prognosis of PTC patients significantly worsened from low-to high-risk.
PTC most frequently shows recurrence to the regional lymph nodes [6] , but distant recurrence is also detected, which is more life-threatening. Therefore, constant follow-up by imaging studies and assessing the thyroglobulin level for patients who underwent total thyroidectomy is important. Since the end of the 1980s, the prevalence of ultrasonography facilitated us to not only evaluate the preoperative disease stage but also to detect local recurrence. However, it remains unclear how long such a careful follow-up is needed for PTC. In this study, therefore, we investigated PTC recurrence and death of PTC patients with lymph node-upper mediastinal node dissection.
Evaluation of clinicopathological features based on pre-and intraoperative findings
For risk classification, we evaluated the characteristics of PTC patients, which were the size of primary lesions and metastatic nodes based on preoperative imaging studies, extrathyroid extension corresponding to T4a in UICC TNM classification [1] , and extranodal tumor extension requiring at least partial resection of adjacent organs based on intraoperative findings. We set the cutoff at the age of 55 years because this cutoff most keenly reflected the patients' prognosis [5] . We previously showed that, in the subset of patients with clinical lateral node metastasis, node metastasis 3 cm or larger and extranodal tumor extension significantly predicted a poorer prognosis [7] . Furthermore, we also demonstrated that extranodal tumor extension was an independent predictor of carcinoma death of PTC patients [8] . Backgrounds and clinicopathological features in our series of patients are summarized in Table 1 .
Risk classification
We previously established a risk classification system based on our previous findings of prognostic factors [5, 7, 8] , which is summarized in Table 2. and distant recurrence-free survival for 5 years after initial surgery, and compared them with the prognosis of patients in the entire series.
Patients and Methods

Patients
We enrolled 5,784 patients who underwent initial and locally curative surgery for PTC without distant metastasis at diagnosis between 1987 and 1996. They consisted of 609 males and 5,175 females, and their ages ranged from 8 to 87 years (average: 50.0 years). Patients who had other thyroid malignancies such as follicular, medullary, and anaplastic carcinomas and malignant lymphoma and who were followed less than 1 year after initial surgery were excluded from our series.
Preoperative evaluation
All patients underwent imaging studies including ultrasonography to evaluate primary lesions and lymph node metastasis. Sizes of primary lesions and lymph node metastasis, if detected, were measured on ultrasonography. Chest CT scan was also performed to evaluate lung metastasis
Surgery
All patients underwent locally curative surgery for PTC. Total or near total thyroidectomy was performed in 2,954 patients and the remaining 2,830 underwent limited thyroidectomy such as subtotal thyroidectomy, lobectomy with isthmectomy, and isthmectomy. Regarding lymph node dissection, 4,373 patients underwent modified radical neck dissection and central node dissection, 1,139 underwent central node dissection only, and the remaining 272 did not undergo lymph node dissection. Three patients also underwent 
Results
Recurrences to the lymph node and distant organs were detected in 457 (7.9%) and 178 (3.1%) patients in Group I, respectively. Sixty-seven patients (1.2%) in Group I died of PTC. In Group II, 197 (5.1%) and 84 (1.7%) patients showed lymph node and distant recurrence, respectively. Twenty-seven patients (0.5%) died of PTC. Table 3 summarizes the number of patients who showed lymph node and distant recurrences and died of PTC according to the risk classification of both groups. The incidences of carcinoma recurrence and carcinoma death of patients in Group I were higher than those in Group II except for the carcinoma death rate in low-risk patients. The ratio of the number of carcinoma recurrences and carcinoma deaths within 5 years to the entire period in intermediate and high-risk patients were higher than those in low-risk patients.
We compared the prognosis between these two groups by the Kaplan-Meier method. Follow-up periods of Group II patients were initiated from 5 years after surgery, as indicated above. Fig. 1 shows the KaplanMeier curves of lymph node-recurrence free survival (LN-RFS) in low-, intermediate, and high-risk patients of Groups I and II. Table 4 indicates the results of 5-and 10-year LN-RFS rates. In Group I, LN-RFS significantly worsened from low-to high-risk. In Group II, although LN-RFS of intermediate-risk patients did not differ from that of low-risk patients, LN-RFS of high-risk patients was significantly poorer than that of intermediate-risk patients. In each risk classification, LN-RFS of patients in Group II was significantly or tended to be better than that of Group I patients (p = 0.0112 in low-
Postoperative evaluation of recurrence
We normally follow patients by ultrasonography with chest roentogenography and/or CT scan once or twice per year. Recurrence was detected by various imaging studies such as ultrasonography, CT scan, PET-CT, and 131 I scintigraphy. We regarded patients as exhibiting recurrence only when recurred lesions were detected on imaging studies.
Grouping PTC patients in our series
We formed two groups with our patients. One was the entire group (Group I) including all 5,784 patients in our series. Another group consisted of 5,065 patients with lymph node-and distant recurrence-free survival (DFS) for 5 years, designated as Group II. Recurrence to the remnant thyroid was not counted. Follow-up periods of patients in Group II were from 5 years after the initial surgery. For example, follow-up period of the patient who was followed for 6 years was 6 years as Group I and 1 year as Group II. Of the 5,784 Group I patients, 4,991, 399, and 394 were classified as low-, intermediate-, and high-risk, respectively. Group II consisted of 4,467 low-, 326 intermediate, and 272 high-risk patients. Postoperative follow-up periods ranged from 1 to 25.2 years (average: 11.7 years) in Group I and from 1 to 20.2 years (average: 7.6 years) in Group II.
Statistical analyses
The Kaplan-Meier method and log rank test were adopted to analyze time-dependent variables. These analyses were performed using StatFlex. A p-value less than 0.05 was regarded as significant and a p-value 0.05 or larger but smaller than 0.1 was regarded as marginal. Kaplan-Meier curves of distant recurrence-free survival (DRFS) of the 6 subsets of PTC patients are summarized in Fig. 2 and their 5-and 10-year DRFS rates are shown in Table 5 . In both groups, DRFS rates sig- However, the LN-RFS rate in high-risk patients in Group II was significantly poorer than that in intermediate-and low-risk patients in Group I, indicating that high-risk should not be downwardly revised even after DFS for 5 years for lymph node recurrence.
Unlike lymph node recurrence, the distant recurrence rate did not improve in all classifications even after DFS for 5 years by the Kaplan-Meier method. Furthermore, DRFS of intermediate-risk patients in Group II was significantly poorer than that of low-risk patients in Group I, and high-risk patients in Group II were significantly more likely to show distant recurrence than low-and intermediate-risk patients in Group I. These findings indicate that the downward revision of risk classification for DRFS for intermediate-and high-risk patients is not appropriate even after 5-year DFS, and careful follow-up for distant recurrence of these patients is required thereafter.
The 10-year CSS rate of high-risk patients in Group II was 93.4%, which was higher than that of those in Group I (88.1%). However, by the Kaplan-Meier method, it was not evident that, in all classifications, CSS significantly improved for patients with DFS for 5 years. Similar to distant recurrence, high-risk patients in Group II were significantly more likely to die of carcinoma than intermediate-and low-risk patients in Group I, and CSS of intermediate-risk patients in Group II was significantly poorer than that of low-risk patients in Group I. It is therefore suggested that, even though patients survived with no lymph node or distant recurrence for 5 years after surgery, the risk of carcinoma death of intermediate-and high-risk patients did not significantly decrease, and the downgrading of risk classification of these patients is not appropriate.
Sugitani et al. showed that high-risk patients without distant metastasis who had a disease-free interval for 3 years showed an excellent prognosis [4] . The 10-year CSS rate of these patients was 96%, although the 10-year CSS rate of high-risk patients in the entire group was low, at 69%. In contrast to our study, 32 of 106 high-risk patients in their series had distant metastasis on initial surgery. As many as 17 (53%) of these 32 patients died of PTC, and the 10-year CSS rate of these patients was very low, at 33%. Although the incidence of high-risk patients in their series was higher, at and 10-year CSS of these subsets are summarized in Table 6 . CSS of patients also came to be poorer from low-to high-risk in both groups. CSS of Group II patients did not differ from that of those in Group I in the same classification. The 10-year CSS rate of highrisk patients in Group II was 93.4%, which was higher than that of those in Group I (88.1%), but the difference was not significant (p = 0.3336). CSS of highrisk patients in Group II was significantly poorer than that of low-and intermediate-risk patients in Group I (p < 0.0001 and p = 0.0006, respectively). CSS of intermediate-risk patients in Group II was also poorer than that of low-risk patients in Group I (p < 0.0001).
Discussion
In this study, we investigated the prognosis of PTC patients who did not show lymph node or distant recurrence for 5 years after initial surgery, and compared it with the prognosis of PTC patients in the entire series. We demonstrated that more than half of intermediateand high-risk patients with carcinoma recurrence or carcinoma death during follow-up showed carcinoma recurrence or died of carcinoma within 5 years after follow-up, and these incidences were higher than those of low-risk patients. These findings suggest that PTC patients with aggressive characteristics are more likely to show recurrence or die of carcinoma in early periods after surgery than low-risk patients.
In the analysis using the Kaplan-Meier method, LN-RFS in Group I patients was significantly poorer than in Group II patients in each risk classification. It is therefore suggested that LN-RFS significantly improved after DFS for 5 years. Furthermore, LN-RFS 18%, than that in our series, which was 7%, the number of patients in their series was smaller than that of our series. These may explain, at least in part, the discrepancy between the results of these two studies.
In summary, we showed that the lymph node recurrence rate, but not distant recurrence rate and carcinoma death rate, significantly improved after DFS for 5 years after the initial surgery in each risk classification. Although intermediate-risk patients after DFS for
